Published in Medical Letter on the CDC and FDA, January 20th, 2008
The LibiGel Phase III safety study protocol was finalized after meetings and discussions with FDA representatives from the Division of Reproductive and Urologic Products, the Division of Cardio-Renal Products and the Office of Biometrics III (statistics). The primary focus of BioSante's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA